Navigation Links
WuXi PharmaTech Selects Labcyte POD(TM) 810 Platform for High-Throughput Screening
Date:12/7/2009

SHANGHAI, Dec. 7 /PRNewswire-Asia/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, announced today it has purchased a Labcyte POD(TM) 810 plate assembler equipped with an Echo(R) 555 acoustic liquid handler for its work in high- throughput screening and secondary screening. WuXi PharmaTech joins the growing number of pharmaceutical companies worldwide that have incorporated the POD system into their compound management and HTS processes.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

"With this technology WuXi will remain the leader in pharmaceutical outsourcing-this demonstrates our continuous efforts to build both capabilities and capacity to help our partners to improve the success of discovery and shorten development time," commented Dr Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech.

"Acoustic liquid handling is clearly the method of choice in drug discovery," said Dr. Qiang Lu, Vice President of Discovery Biology of WuXi PharmaTech. "We are very pleased to incorporate the POD 810 into our systems. It will make our drug discovery efforts significantly more productive while it reduces cost through the elimination of disposable plastic tips. We know that acoustic liquid handling will significantly improve the quality of the data we generate. We are looking forward to a continuing relationship with Labcyte."

The POD 810 plate assembler, a walk-away, out-of-the-box solution, transforms any Echo acoustic liquid handler into a Plates-On-Demand instrument. The POD system is controlled by its revolutionary Intellectual Scheduler with built-in intelligence to automatically adjust workflow to maximize productivity.

"The POD platform is uniquely positioned to advance method standardization across global sites," said Mark Fischer-Colbrie, president and CEO of Labcyte Inc. "It eliminates the unnecessary delays associated with customized integration."

"We are very pleased WuXi PharmaTech decided to acquire a Labcyte POD system," said Sanger Chang, General Manager of Tekon Biotech. "Our exclusive relationship with Labcyte is further validation of our efforts to be the leading supplier of instrument systems for pharmaceutical research to the Chinese market by providing the highest level of technical support and service."

    For more information, please contact:

    WuXi PharmaTech (Cayman) Inc.

     Ronald Aldridge (for investors)
     Director of Investor Relations
     Tel:   +1-201-585-2048
     Email: ir@wuxiapptec.com

     Stephanie Liu (for the media)
     WuXi PharmaTech (Cayman) Inc.
     Tel:   +86-21-5046-4362
     Email: pr@wuxiapptec.com

SOURCE WuXi PharmaTech (Cayman) Inc.


'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. WuXi PharmaTech Schedules 2007 Second Quarter Earnings Release on Thursday, September 6, 2007
2. WuXi PharmaTech Announces Second Quarter 2007 Results
3. WuXi PharmaTech (NYSE: WX) Wins Both Deloitte Technology Fast 50 China and Deloitte Technology Fast 500 Asia
4. WuXi PharmaTech (NYSE: WX) Ranked the 28th of Deloitte Technology Fast 50 China
5. Massachusetts Governor Deval L. Patrick Pays Visit to WuXi PharmaTech
6. Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology
7. WuXi PharmaTech (NYSE: WX) Promotes Edward Hu to COO
8. WuXi PharmaTech to Acquire AppTec Laboratory Services, Inc.
9. WuXi PharmaTech (NYSE: WX) CEO Honored among the 2007 China Top 10 Influential Entrepreneurs
10. Quest PharmaTech and BC Cancer Agency to Develop Immuno Photodynamic Therapies for Lung Cancer
11. WuXi PharmaTech Completes Acquisition of AppTec
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... CALGARY , Dec. 5, 2016 /PRNewswire/ - ... announced  that the independent Data and Safety Monitoring ... trial in high-risk cardiovascular disease (CVD) patients has ... that the study should continue as planned without ... and noted that no safety or efficacy concerns ...
(Date:12/5/2016)... N.J. , Dec. 5, 2016  Eisai ... 3 open-label two-year study of rufinamide, which were ... American Epilepsy Society (AES) held from December 2-6 ... of final two-year safety, tolerability and cognitive data ... rufinamide experienced similar safety and tolerability profiles, cognitive ...
(Date:12/5/2016)... , December 5, 2016 The ... with almost $108 billion of revenue and some $890 ... were spent on global biopharmaceuticals, and this figure is ... Stock-Callers.com has lined up these four equities for assessment: ... Pharmaceuticals Inc. (NASDAQ: ACAD ), Acorda Therapeutics ...
(Date:12/4/2016)... ... December 03, 2016 , ... ... A microbiome impact grant award has been made to Dr. Renato Polimanti of ... and drinking on the oral microbiome. Grant proposals have been vetted by the ...
Breaking Biology Technology:
(Date:11/15/2016)... Research and Markets has announced the addition ... report to their offering. ... The global ... from USD 6.21 Billion in 2016, growing at a CAGR of ... bioinformatics market is driven by the growing demand for nucleic acid ...
(Date:11/14/2016)... , Nov. 14, 2016  Based on ... market, Frost & Sullivan recognizes FST Biometrics ... Award for Visionary Innovation Leadership. FST Biometrics ... biometric identification market by pioneering In Motion ... for instant, seamless, and non-invasive verification. This ...
(Date:6/22/2016)... June 22, 2016  The American College of Medical Genetics ... Executive Magazine as one of the fastest-growing trade shows ... at the Bellagio in Las Vegas . ... percentage of growth in each of the following categories: net ... and number of attendees. The 2015 ACMG Annual Meeting was ...
Breaking Biology News(10 mins):